Cargando…

Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis

AIMS: Hyperglucagonemia occurs in the pathogenesis of type 2 diabetes mellitus (T2DM). In this meta-analysis, we summarized the effects of DPP4 inhibitors on glucagon levels in patients with T2DM. MATERIALS AND METHODS: Randomized controlled trials (RCTs) comparing the influence of DPP4 inhibitors o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chai, Shangyu, Zhang, Ruya, Zhang, Ye, Carr, Richard David, Zheng, Yiman, Rajpathak, Swapnil, Ji, Linong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597445/ https://www.ncbi.nlm.nih.gov/pubmed/36313782 http://dx.doi.org/10.3389/fendo.2022.994944

Ejemplares similares

Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
por: Chai, Shangyu, et al.
Publicado: (2022)

Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis
por: Chai, Shangyu, et al.
Publicado: (2023)

Effect of Dipeptidyl Peptidase 4 Inhibitors Used in Combination with Insulin Treatment in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis
por: Yang, Jin, et al.
Publicado: (2020)

Retrospective Cohort Analysis of the Reduced Burden of Hypoglycemia Associated with Dipeptidyl Peptidase-4 Inhibitor Use in Patients with Type 2 Diabetes Mellitus
por: Tang, Yuexin, et al.
Publicado: (2018)

Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging
por: Cao, Fen, et al.
Publicado: (2021)

Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier
por: Zhao, Dandan, et al.
Publicado: (2018)

The Multiple Biological Functions of Dipeptidyl Peptidase-4 in Bone Metabolism
por: Yang, Qiu, et al.
Publicado: (2022)

Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes
por: Liu, Xu, et al.
Publicado: (2021)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Addition of dipeptidyl peptidase‐4 inhibitors to insulin treatment in type 2 diabetes patients: A meta‐analysis
por: Yang, Wenjia, et al.
Publicado: (2017)

Direct head‐to‐head comparison of glycaemic durability of dipeptidyl peptidase‐4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta‐analysis of long‐term randomized controlled trials
por: Chen, Kang, et al.
Publicado: (2017)

Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?
por: Michel, Martin C., et al.
Publicado: (2008)

Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents
por: Mousa, Shaker A., et al.
Publicado: (2019)

Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: Zhang, Fang, et al.
Publicado: (2020)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats
por: Zhou, Xiaoyan, et al.
Publicado: (2015)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Dipeptidyl Peptidase-4 Inhibitor (Vildagliptin) Improves Glycemic Control After Meal Tolerance Test by Suppressing Glucagon Release
por: Okamoto, Aki, et al.
Publicado: (2014)

Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes
por: Yanagimachi, Tsuyoshi, et al.
Publicado: (2020)

Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
por: Dave, Darshan J.
Publicado: (2011)

Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
por: Esaki, Hiroki, et al.
Publicado: (2017)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
por: Nishida, Yayoi, et al.
Publicado: (2020)

A Case of Euglycemic Diabetic Ketoacidosis (DKA), Influenza, and a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
por: Jeong, Su Hyun, et al.
Publicado: (2023)

In Silico Approaches Applied to the Study of Peptide Analogs of Ile-Pro-Ile in Relation to Their Dipeptidyl Peptidase IV Inhibitory Properties
por: Nongonierma, Alice B., et al.
Publicado: (2018)

Health economic evaluation of dipeptidyl peptidase-4 inhibitors
por: Garg, Vishvas
Publicado: (2011)

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
por: Singh, Awadhesh Kumar
Publicado: (2014)

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
por: Shoombuatong, Watshara, et al.
Publicado: (2015)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome
por: Kim, Kwang-il
Publicado: (2018)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
por: Tasanen, Kaisa, et al.
Publicado: (2019)

Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?
por: Yazbeck, R., et al.
Publicado: (2021)

Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
por: Yin, Ruili, et al.
Publicado: (2022)

Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials
por: Esposito, Katherine, et al.
Publicado: (2014)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review
por: Batel-Marques, Francisco, et al.
Publicado: (2019)

The Effects of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease Risks in Type 2 Diabetes Mellitus
por: Yousefzadeh, Pegah, et al.
Publicado: (2013)

The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Groups
por: Kountz, David
Publicado: (2013)

Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
por: Yagi, Shusuke, et al.
Publicado: (2015)

Associations of dipeptidyl peptidase‐4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus
por: Sato, Akihiko, et al.
Publicado: (2015)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
por: Lin, Yi-Hsin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_41uu1k4390dhf01bog0ibt2gmm